The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer

Osama Nusrat, Jimmy Belotte, Nicole M. Fletcher, Ira Memaj, Mohammed G. Saed, Michael P. Diamond, Ghassan M. Saed

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: Chemoresistance remains a major challenge in the treatment of ovarian cancer. As part of a survival mechanism, tumor cells have been shown to release proangiogenic factors, such as vascular endothelial growth factor (VEGF), through a mechanism that involves the upregulation of hypoxia-induced factor (HIF)-1α. The objective of this study was to compare the expression of VEGF and its receptors (R1 and R2) as well as HIF-1α in chemoresistant epithelial ovarian cancer (EOC) cells to their chemosensitive counterparts and determine their impact on angiogenesis.

METHODS: Two human EOC cell lines, MDAH-2774 and SKOV-3, and their cisplatin- or taxotere-resistant counterparts were used. Total RNA and protein were subjected to real-time reverse transcriptase-polymerase chain reaction, immunoprecipitation/Western blot and enzyme-linked immunosorbent assay to evaluate the expression of VEGF, VEGF receptors (R1 and R2), and HIF-1α. Angiogenesis was assessed with an in vitro angiogenesis assay. Data were analyzed using independent Student t tests and chi-square.

RESULTS: Both taxotere- and cisplatin-resistant MDAH-2774 and SKOV-3 EOC cell lines manifested a significant decrease in VEGF, VEGF receptors, HIF-1α messenger RNA, and protein levels as compared to their chemosensitive counterparts. There was a significant decrease in the number and thickness of polygon blood vessel formation in chemoresistant EOC cells compared to chemosensitive counterparts.

CONCLUSION: Cisplatin- and taxotere-resistant EOC cells are characterized by lower VEGF, VEGF receptors, and HIF-1α, and decreased angiogenesis. These findings may indicate a decrease in drug delivery at the tumor site, hence allowing the persistence of chemoresistant EOC cells.

Original languageEnglish (US)
Pages (from-to)1484-1492
Number of pages9
JournalReproductive Sciences
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

docetaxel
Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
Cisplatin
Cell Line
Chi-Square Distribution
Reverse Transcriptase Polymerase Chain Reaction
Immunoprecipitation
Ovarian Neoplasms
Blood Vessels
Ovarian epithelial cancer
Real-Time Polymerase Chain Reaction
Neoplasms
Proteins
Up-Regulation
Western Blotting
Enzyme-Linked Immunosorbent Assay
Hypoxia
RNA
Students

Keywords

  • and hypoxia-inducible factor-1α
  • chemoresistance
  • ovarian cancer
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. / Nusrat, Osama; Belotte, Jimmy; Fletcher, Nicole M.; Memaj, Ira; Saed, Mohammed G.; Diamond, Michael P.; Saed, Ghassan M.

In: Reproductive Sciences, Vol. 23, No. 11, 01.11.2016, p. 1484-1492.

Research output: Contribution to journalArticle

Nusrat, O, Belotte, J, Fletcher, NM, Memaj, I, Saed, MG, Diamond, MP & Saed, GM 2016, 'The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer', Reproductive Sciences, vol. 23, no. 11, pp. 1484-1492. https://doi.org/10.1177/1933719116645191
Nusrat, Osama ; Belotte, Jimmy ; Fletcher, Nicole M. ; Memaj, Ira ; Saed, Mohammed G. ; Diamond, Michael P. ; Saed, Ghassan M. / The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. In: Reproductive Sciences. 2016 ; Vol. 23, No. 11. pp. 1484-1492.
@article{da1f42f079834774890c44f5f4c754be,
title = "The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer",
abstract = "OBJECTIVE: Chemoresistance remains a major challenge in the treatment of ovarian cancer. As part of a survival mechanism, tumor cells have been shown to release proangiogenic factors, such as vascular endothelial growth factor (VEGF), through a mechanism that involves the upregulation of hypoxia-induced factor (HIF)-1α. The objective of this study was to compare the expression of VEGF and its receptors (R1 and R2) as well as HIF-1α in chemoresistant epithelial ovarian cancer (EOC) cells to their chemosensitive counterparts and determine their impact on angiogenesis.METHODS: Two human EOC cell lines, MDAH-2774 and SKOV-3, and their cisplatin- or taxotere-resistant counterparts were used. Total RNA and protein were subjected to real-time reverse transcriptase-polymerase chain reaction, immunoprecipitation/Western blot and enzyme-linked immunosorbent assay to evaluate the expression of VEGF, VEGF receptors (R1 and R2), and HIF-1α. Angiogenesis was assessed with an in vitro angiogenesis assay. Data were analyzed using independent Student t tests and chi-square.RESULTS: Both taxotere- and cisplatin-resistant MDAH-2774 and SKOV-3 EOC cell lines manifested a significant decrease in VEGF, VEGF receptors, HIF-1α messenger RNA, and protein levels as compared to their chemosensitive counterparts. There was a significant decrease in the number and thickness of polygon blood vessel formation in chemoresistant EOC cells compared to chemosensitive counterparts.CONCLUSION: Cisplatin- and taxotere-resistant EOC cells are characterized by lower VEGF, VEGF receptors, and HIF-1α, and decreased angiogenesis. These findings may indicate a decrease in drug delivery at the tumor site, hence allowing the persistence of chemoresistant EOC cells.",
keywords = "and hypoxia-inducible factor-1α, chemoresistance, ovarian cancer, vascular endothelial growth factor",
author = "Osama Nusrat and Jimmy Belotte and Fletcher, {Nicole M.} and Ira Memaj and Saed, {Mohammed G.} and Diamond, {Michael P.} and Saed, {Ghassan M.}",
note = "{\circledC} The Author(s) 2016.",
year = "2016",
month = "11",
day = "1",
doi = "10.1177/1933719116645191",
language = "English (US)",
volume = "23",
pages = "1484--1492",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer

AU - Nusrat, Osama

AU - Belotte, Jimmy

AU - Fletcher, Nicole M.

AU - Memaj, Ira

AU - Saed, Mohammed G.

AU - Diamond, Michael P.

AU - Saed, Ghassan M.

N1 - © The Author(s) 2016.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - OBJECTIVE: Chemoresistance remains a major challenge in the treatment of ovarian cancer. As part of a survival mechanism, tumor cells have been shown to release proangiogenic factors, such as vascular endothelial growth factor (VEGF), through a mechanism that involves the upregulation of hypoxia-induced factor (HIF)-1α. The objective of this study was to compare the expression of VEGF and its receptors (R1 and R2) as well as HIF-1α in chemoresistant epithelial ovarian cancer (EOC) cells to their chemosensitive counterparts and determine their impact on angiogenesis.METHODS: Two human EOC cell lines, MDAH-2774 and SKOV-3, and their cisplatin- or taxotere-resistant counterparts were used. Total RNA and protein were subjected to real-time reverse transcriptase-polymerase chain reaction, immunoprecipitation/Western blot and enzyme-linked immunosorbent assay to evaluate the expression of VEGF, VEGF receptors (R1 and R2), and HIF-1α. Angiogenesis was assessed with an in vitro angiogenesis assay. Data were analyzed using independent Student t tests and chi-square.RESULTS: Both taxotere- and cisplatin-resistant MDAH-2774 and SKOV-3 EOC cell lines manifested a significant decrease in VEGF, VEGF receptors, HIF-1α messenger RNA, and protein levels as compared to their chemosensitive counterparts. There was a significant decrease in the number and thickness of polygon blood vessel formation in chemoresistant EOC cells compared to chemosensitive counterparts.CONCLUSION: Cisplatin- and taxotere-resistant EOC cells are characterized by lower VEGF, VEGF receptors, and HIF-1α, and decreased angiogenesis. These findings may indicate a decrease in drug delivery at the tumor site, hence allowing the persistence of chemoresistant EOC cells.

AB - OBJECTIVE: Chemoresistance remains a major challenge in the treatment of ovarian cancer. As part of a survival mechanism, tumor cells have been shown to release proangiogenic factors, such as vascular endothelial growth factor (VEGF), through a mechanism that involves the upregulation of hypoxia-induced factor (HIF)-1α. The objective of this study was to compare the expression of VEGF and its receptors (R1 and R2) as well as HIF-1α in chemoresistant epithelial ovarian cancer (EOC) cells to their chemosensitive counterparts and determine their impact on angiogenesis.METHODS: Two human EOC cell lines, MDAH-2774 and SKOV-3, and their cisplatin- or taxotere-resistant counterparts were used. Total RNA and protein were subjected to real-time reverse transcriptase-polymerase chain reaction, immunoprecipitation/Western blot and enzyme-linked immunosorbent assay to evaluate the expression of VEGF, VEGF receptors (R1 and R2), and HIF-1α. Angiogenesis was assessed with an in vitro angiogenesis assay. Data were analyzed using independent Student t tests and chi-square.RESULTS: Both taxotere- and cisplatin-resistant MDAH-2774 and SKOV-3 EOC cell lines manifested a significant decrease in VEGF, VEGF receptors, HIF-1α messenger RNA, and protein levels as compared to their chemosensitive counterparts. There was a significant decrease in the number and thickness of polygon blood vessel formation in chemoresistant EOC cells compared to chemosensitive counterparts.CONCLUSION: Cisplatin- and taxotere-resistant EOC cells are characterized by lower VEGF, VEGF receptors, and HIF-1α, and decreased angiogenesis. These findings may indicate a decrease in drug delivery at the tumor site, hence allowing the persistence of chemoresistant EOC cells.

KW - and hypoxia-inducible factor-1α

KW - chemoresistance

KW - ovarian cancer

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84991299997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991299997&partnerID=8YFLogxK

U2 - 10.1177/1933719116645191

DO - 10.1177/1933719116645191

M3 - Article

C2 - 27122375

VL - 23

SP - 1484

EP - 1492

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 11

ER -